Biomark Diagnostics Inc. (DB: 20B)
Health Care · Biotechnology · CA
€0.29
-10.06% today · +41.6% 1Y
Biomark Diagnostics Inc. (DB: 20B) operates in the Biotechnology industry within the Health Care sector. The company is valued at $35.55M.
Over the last twelve months the share price has gained 41.6%, trading between 0.15 and 0.42.
Tweenvest scores Biomark Diagnostics Inc. across four factors: quality 11/100, value 68/100. Its strongest factor is value.
20B price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $35.55M
- Revenue (TTM)
- $42.83K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- -0.31
- 52-week high
- €0.42
- 52-week low
- €0.15
- Avg volume (3M)
- —
- Shares outstanding
- 106.48M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €884.60 | -1.93% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.